{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:07:25Z","timestamp":1793945245314,"version":"4.8.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.radonc.2023.109486","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T05:03:53Z","timestamp":1674623033000},"page":"109486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-0051","authenticated-orcid":false,"given":"Ingrid","family":"Sidibe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8481-5941","authenticated-orcid":false,"given":"Fatima","family":"Tensaouti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gilhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Cabarrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Filleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-6266","authenticated-orcid":false,"given":"Franck","family":"Desmoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7904-5882","authenticated-orcid":false,"given":"Soleakhena","family":"Ken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Truc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Pierre","family":"Sunyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Charissoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Magn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Albert","family":"Lotterie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9447-3092","authenticated-orcid":false,"given":"Margaux","family":"Roques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7200-0139","authenticated-orcid":false,"given":"Patrice","family":"P\u00e9ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cohen-Jonathan Moyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0103-7935","authenticated-orcid":false,"given":"Anne","family":"Laprie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109486_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000464374","article-title":"Epidemiology of intracranial gliomas","volume":"30","author":"Ostrom","year":"2018","journal-title":"Intracranial Gliomas Part I - Surgery"},{"key":"10.1016\/j.radonc.2023.109486_b0010","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.109486_b0015","doi-asserted-by":"crossref","first-page":"103188","DOI":"10.1016\/j.critrevonc.2020.103188","article-title":"Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review: Part 1 - Molecular, morphological and clinical features","volume":"157","author":"Le F\u00e8vre","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.radonc.2023.109486_b0020","doi-asserted-by":"crossref","first-page":"103230","DOI":"10.1016\/j.critrevonc.2021.103230","article-title":"Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 - Radiological features and metric markers","volume":"159","author":"Le F\u00e8vre","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.radonc.2023.109486_b0025","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients","volume":"26","author":"Brandes","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109486_b0030","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas","volume":"9","author":"Brandsma","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109486_b0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cncr.23562","article-title":"Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide","volume":"113","author":"Taal","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2023.109486_b0040","first-page":"601","article-title":"Distinguishing pseudoprogression from true early progression in isocitrate dehydrogenase wild-type glioblastoma by interrogating clinical, radiological, and molecular features","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2023.109486_b0045","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/neuonc\/now091","article-title":"Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy\/temozolomide for newly diagnosed glioblastoma","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2023.109486_b0050","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109486_b0055","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/jmri.26171","article-title":"Pseudoprogression of brain tumors","volume":"48","author":"Thust","year":"2018","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.radonc.2023.109486_b0060","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","article-title":"Response assessment in neuro-oncology clinical trials","volume":"35","author":"Wen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109486_b0065","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1007\/s00330-017-4789-9","article-title":"Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis","volume":"27","author":"van Dijken","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1016\/j.radonc.2023.109486_b0070","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/biomedicines10020285","article-title":"Pseudoprogression in glioblastoma: role of metabolic and functional MRI-systematic review","volume":"10","author":"Sidibe","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.radonc.2023.109486_b0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-019-5317-x","article-title":"Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging","volume":"19","author":"Laprie","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2023.109486_b0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11060-016-2232-8","article-title":"Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?","volume":"130","author":"Khalifa","year":"2016","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2023.109486_b0085","article-title":"Quality control of 3D MRSI data in glioblastoma: Can we do without the experts?","author":"Tensaouti","year":"2021","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.radonc.2023.109486_b0090","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/neuonc\/now058","article-title":"Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas","volume":"18","author":"Albert","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2023.109486_b0095","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/neuonc\/noy133","article-title":"Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients","volume":"21","author":"Kim","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2023.109486_b0100","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.acra.2011.05.006","article-title":"MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury","volume":"18","author":"Elias","year":"2011","journal-title":"Acad Radiol"},{"key":"10.1016\/j.radonc.2023.109486_b0105","doi-asserted-by":"crossref","first-page":"W45","DOI":"10.2214\/AJR.07.3934","article-title":"Developing a clinical decision Model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions","volume":"192","author":"Smith","year":"2009","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.radonc.2023.109486_b0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-007-9341-3","article-title":"Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury","volume":"84","author":"Zeng","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2023.109486_b0115","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.nicl.2016.02.016","article-title":"Advanced MRI increases the diagnostic accuracy of recurrent glioblastoma: Single institution thresholds and validation of MR spectroscopy and diffusion weighted MR imaging","volume":"11","author":"Kazda","year":"2016","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.radonc.2023.109486_b0120","doi-asserted-by":"crossref","first-page":"641023","DOI":"10.1155\/2015\/641023","article-title":"The diagnostic ability of follow-up imaging biomarkers after treatment of glioblastoma in the Temozolomide Era: implications from proton MR spectroscopy and apparent diffusion coefficient mapping","volume":"2015","author":"Bulik","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.radonc.2023.109486_b0125","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijrobp.2014.06.009","article-title":"Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme","volume":"90","author":"Deviers","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109486_b0130","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1007\/s00330-015-4046-z","article-title":"The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic review and meta-analysis","volume":"26","author":"Wang","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.radonc.2023.109486_b0135","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3174\/ajnr.A5485","article-title":"Diagnostic accuracy of centrally restricted diffusion in the differentiation of treatment-related necrosis from tumor recurrence in high-grade gliomas","volume":"39","author":"Zakhari","year":"2018","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.radonc.2023.109486_b0140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13244-019-0724-8","article-title":"Pre-operative apparent diffusion coefficient values and tumour region volumes as prognostic biomarkers in glioblastoma: correlation and progression-free survival analyses","volume":"10","author":"Durand-Mu\u00f1oz","year":"2019","journal-title":"Insights Imaging"},{"key":"10.1016\/j.radonc.2023.109486_b0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jns.2015.02.038","article-title":"Diagnostic accuracy of diffusion MRI with quantitative ADC measurements in differentiating glioma recurrence from radiation necrosis","volume":"351","author":"Zhang","year":"2015","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.radonc.2023.109486_b0150","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2217\/cns-2017-0013","article-title":"Visual inspection of MR relative cerebral blood volume maps has limited value for distinguishing progression from pseudoprogression in glioblastoma multiforme patients","volume":"6","author":"Kerkhof","year":"2017","journal-title":"CNS Oncol"},{"key":"10.1016\/j.radonc.2023.109486_b0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/COC.0000000000000156","article-title":"Longitudinal DSC-MRI for distinguishing tumor recurrence from pseudoprogression in patients with a high-grade glioma","volume":"40","author":"Boxerman","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109486_b0160","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s11060-020-03475-y","article-title":"Differentiation of progressive disease from pseudoprogression using 3D PCASL and DSC perfusion MRI in patients with glioblastoma","volume":"147","author":"Manning","year":"2020","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2023.109486_b0165","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/neuonc\/now148","article-title":"MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis","volume":"19","author":"Patel","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2023.109486_b0170","first-page":"901","article-title":"Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue","volume":"21","author":"Sugahara","year":"2000","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.radonc.2023.109486_b0175","doi-asserted-by":"crossref","first-page":"790674","DOI":"10.3389\/fimmu.2021.790674","article-title":"Advanced imaging techniques for differentiating pseudoprogression and tumor recurrence after immunotherapy for glioblastoma","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.radonc.2023.109486_b0180","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/COC.0b013e318210f54a","article-title":"Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide","volume":"35","author":"Topkan","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109486_b0185","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/neuonc\/not328","article-title":"Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question","volume":"16","author":"Nasseri","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2023.109486_b0190","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/cns.14.42","article-title":"Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival","volume":"3","author":"Gahramanov","year":"2014","journal-title":"CNS Oncol"},{"key":"10.1016\/j.radonc.2023.109486_b0195","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11060-012-0826-3","article-title":"Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme","volume":"108","author":"Rold\u00e1n Urgoiti","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2023.109486_b0200","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11060-019-03124-z","article-title":"Role of postoperative tumor volume in patients with MGMT-unmethylated glioblastoma","volume":"142","author":"Sales","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2023.109486_b0205","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/neuonc\/noy064","article-title":"Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo","volume":"20","author":"Ellingson","year":"2018","journal-title":"Neuro Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023000245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023000245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:25:29Z","timestamp":1759123529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023000245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":41,"alternative-id":["S0167814023000245"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109486","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109486","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109486"}}